Sort
10,766 grants matching “checkpoint inhibitor”
Studies on thymidylate synthase as a tumor-promoting oncogene for development of new allosteric inhibitors for cancer treatment
$342,091Maria Zajac-Kaye · University Of Florida · R01 · FY2016 · CA
Studies on thymidylate synthase as a tumor-promoting oncogene for development of new allosteric inhibitors for cancer treatment
$342,039Maria Zajac-Kaye · University Of Florida · R01 · FY2017 · CA
Replication Stress and DNA Damage Response Drives ESR1 Mutant Metastasis
$342,000Suzanne A Fuqua · Baylor College Of Medicine · R01 · FY2022 · CA
p53 and checkpoint pathways in cancer cell repliction
$342,000University Of Virginia Charlottesville · R01 · FY2004 · CA
Replication Stress and DNA Damage Response Drives ESR1 Mutant Metastasis
$342,000Suzanne A Fuqua · Baylor College Of Medicine · R01 · FY2023 · CA
Replication Stress and DNA Damage Response Drives ESR1 Mutant Metastasis
$342,000Suzanne A Fuqua · Baylor College Of Medicine · R01 · FY2025 · CA
Studies on thymidylate synthase as a tumor-promoting oncogene for development of new allosteric inhibitors for cancer treatment
$341,985Maria Zajac-Kaye · University Of Florida · R01 · FY2018 · CA
Studies on thymidylate synthase as a tumor-promoting oncogene for development of new allosteric inhibitors for cancer treatment
$341,868Maria Zajac-Kaye · University Of Florida · R01 · FY2020 · CA
Role of RON kinase in anti-tumor immune responses
$341,867Alana L Welm · University Of Utah · R01 · FY2022 · CA
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
$341,852Shridar Ganesan · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2012 · CA
Regulation of Vps4 during ESCRT function
$341,850David J Katzmann · Mayo Clinic Rochester · R01 · FY2019 · GM
Regulation of Vps4 during ESCRT function
$341,850David J Katzmann · Mayo Clinic Rochester · R01 · FY2018 · GM
Regulation of Vps4 during ESCRT function
$341,850David J Katzmann · Mayo Clinic Rochester · R01 · FY2017 · GM
Regulation of Vps4 during ESCRT function
$341,850David J Katzmann · Mayo Clinic Rochester · R01 · FY2016 · GM
Immunotherapeutic targeting of MIF-dependent chaperone activity
$341,782Robert A. Mitchell · University Of Louisville · R01 · FY2025 · CA
Project 4
$341,751Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2021 · CA
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma
$341,706Sherie L Morrison · University Of California Los Angeles · R01 · FY2019 · CA
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers
$341,685Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2021 · CA
The replication checkpoint and genomic fidelity in skin
$341,668Paul Nghiem · University Of Washington · R01 · FY2014 · AR
Targeting immune stroma interactions in pancreatic cancer
$341,667Gregory B. Lesinski · Emory University · R01 · FY2023 · CA
Role of an unusual GTPase in DNA damage response and carcinogenesis
$341,652Sam W Lee · Massachusetts General Hospital · R01 · FY2012 · CA
Role of an unusual GTPase in DNA damage response and carcinogenesis
$341,652Sam W Lee · Massachusetts General Hospital · R01 · FY2011 · CA
SPINK7 in allergic inflammation
$341,520Marc E. Rothenberg · Cincinnati Childrens Hosp Med Ctr · U19 · FY2017 · AI
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$341,431David E Fisher · Massachusetts General Hospital · P01 · FY2021 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
$341,315Goldy C George · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA